UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of principal executive Offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: |
|
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended September 30, 2024. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release issued by MEI Pharma, Inc., dated November 14, 2024. |
|
|
|
104 |
|
Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Date: |
November 12, 2024 |
By: |
/s/ Justin J. File |
|
|
|
Acting Chief Executive Officer, Chief Financial Officer and Secretarty |
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
Reaffirms Continuation of Evaluation of Strategic Alternatives
SAN DIEGO--(BUSINESS WIRE) — November 12, 2024 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024.
As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.
During the first quarter of fiscal year 2025, the Company commenced cash preservation efforts that include a reduction-in-force, which will continue in stages as the Company’s operational and strategic direction evolves.
There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
As of September 30, 2024, MEI had $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.
Forward-Looking Statements
Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and
other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
Contact:
Justin J. File
858-898-0976
investor@meipharma.com
MEI PHARMA, INC. |
|
||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
||||||
(In thousands, except par value amounts) |
|
||||||
|
|
|
|
|
|
||
|
September 30, |
|
|
June 30, |
|
||
|
2024 |
|
|
2024 |
|
||
|
(Unaudited) |
|
|
(Audited) |
|
||
ASSETS |
|
||||||
Current assets: |
|
|
|
|
|
||
Cash and cash equivalents |
$ |
6,952 |
|
|
$ |
3,705 |
|
Short-term investments |
|
19,953 |
|
|
|
34,640 |
|
Prepaid expenses and other current assets |
|
840 |
|
|
|
2,424 |
|
Total current assets |
|
27,745 |
|
|
|
40,769 |
|
Operating lease right-of-use asset |
|
— |
|
|
|
214 |
|
Property and equipment, net |
|
5 |
|
|
|
392 |
|
Total assets |
$ |
27,750 |
|
|
$ |
41,375 |
|
|
|
|
|
|
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
||||||
Current liabilities: |
|
|
|
|
|
||
Accounts payable |
$ |
976 |
|
|
$ |
3,168 |
|
Accrued liabilities |
|
1,896 |
|
|
|
5,187 |
|
Total current liabilities |
|
2,872 |
|
|
|
8,355 |
|
Total liabilities |
|
2,872 |
|
|
|
8,355 |
|
|
|
|
|
|
|
||
Stockholders' equity: |
|
|
|
|
|
||
Preferred stock, $0.01 par value; 100 shares authorized; |
|
|
|
|
|
||
none outstanding |
|
— |
|
|
|
— |
|
Common stock, $0.00000002 par value; 226,000 shares |
|
|
|
|
|
||
authorized; 6,663 shares issued and outstanding |
|
|
|
|
|
||
at September 30, 2024 and June 30, 2024, respectively |
|
— |
|
|
|
— |
|
Additional paid-in-capital |
|
421,104 |
|
|
|
421,239 |
|
Accumulated deficit |
|
(396,226 |
) |
|
|
(388,219 |
) |
Total stockholders' equity |
|
24,878 |
|
|
|
33,020 |
|
Total liabilities and stockholders' equity |
$ |
27,750 |
|
|
$ |
41,375 |
|
|
|
|
|
|
|
||
MEI PHARMA, INC. |
|
|||||||
CONSOLIDATED STATEMENTS OF OPERATIONS |
|
|||||||
(In thousands, except per share amounts) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
For the Three Months Ended September 30, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
|
|
(Unaudited) |
|
|||||
|
|
|
|
|
|
|
||
Revenues |
|
$ |
— |
|
|
$ |
65,297 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
3,163 |
|
|
|
3,485 |
|
General and administrative |
|
|
5,189 |
|
|
|
6,531 |
|
Total operating expenses |
|
|
8,352 |
|
|
|
10,016 |
|
(Loss) income from operations |
|
|
(8,352 |
) |
|
|
55,281 |
|
Other income (expense): |
|
|
|
|
|
|
||
Interest and dividend income |
|
|
355 |
|
|
|
1,094 |
|
Other expense, net |
|
|
(10 |
) |
|
|
(1 |
) |
Net (loss) income |
|
$ |
(8,007 |
) |
|
$ |
56,374 |
|
|
|
|
|
|
|
|
||
Net (loss) income per share - basic and diluted |
|
$ |
(1.20 |
) |
|
$ |
8.46 |
|
|
|
|
|
|
|
|
||
Weighted-average shares used in computing net |
|
|
6,663 |
|
|
|
6,663 |
|
|
|
|
|
|
|
|
||